GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Raia Drogasil SA (BSP:RADL3) » Definitions » Valuation Rank

Raia Drogasil (BSP:RADL3) Valuation Rank


View and export this data going back to 1995. Start your Free Trial

What is Raia Drogasil Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Raia Drogasil Valuation Rank Related Terms

Thank you for viewing the detailed overview of Raia Drogasil's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Raia Drogasil (BSP:RADL3) Business Description

Traded in Other Exchanges
Address
Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-9000
Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries.